Welcome to chemicalbook!
400-158-6606
Try our best to find the right business for you.
Do not miss inquiry messages Please log in to view all inquiry messages.

Welcome back!

ChemicalBook > Product Catalogue >API >Blood System Drugs >Anticoagulant and Antiplatelet Drugs >Rivaroxaban

Rivaroxaban

Rivaroxaban Structure
  • ₹0
  • Product name: Rivaroxaban
  • CAS: 366789-02-8
  • MF: C19H18ClN3O5S
  • MW: 435.88
  • EINECS:685-132-2
  • MDL Number:MFCD11974010
  • Synonyms:(S)-Rivaroxaban;5-Chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl]-2-thiophenecarboxamide;BAY 59-7939;Rivaroxaban Isomer;Rivaroxaban;5-Chloro-N-(((5S)-2-oxo-3-(4-(3-oxomorpholin-4-yl)phenyl)-1,3-oxazolidin-5-yl)methyl)thiophene-2-carboxamide;2-Thiophenecarboxamide, 5-chloro-N-[[(5S)-2-oxo-3-[4-(3-oxo-4-morpholinyl)phenyl]-5-oxazolidinyl]methyl];(S)-5-Chloro-N-((2-oxo-3-(4-(3-oxomorpholino)phenyl)-oxazolidin-5-yl)methyl)thiophene-2-carboxami
Manufacturer Product number Product description Packaging Price Updated Buy

Properties

Melting point :228-229°C
Boiling point :732.6±60.0 °C(Predicted)
Density :1.460±0.06 g/cm3(Predicted)
storage temp. :Inert atmosphere,2-8°C
solubility :insoluble in H2O; insoluble in EtOH; ≥13.9 mg/mL in DMSO with gentle warming
form :solid
pka :13.36±0.46(Predicted)
color :White to off-white
InChI :InChI=1S/C19H18ClN3O5S/c20-16-6-5-15(29-16)18(25)21-9-14-10-23(19(26)28-14)13-3-1-12(2-4-13)22-7-8-27-11-17(22)24/h1-6,14H,7-11H2,(H,21,25)/t14-/m0/s1
InChIKey :KGFYHTZWPPHNLQ-AWEZNQCLSA-N
SMILES :C1(C(NC[C@@H]2OC(=O)N(C3=CC=C(N4CCOCC4=O)C=C3)C2)=O)SC(Cl)=CC=1

Safety Information

Symbol(GHS): GHS hazard pictograms
Signal word:
Hazard statements:
Code Hazard statements Hazard class Category Signal word Pictogram P-Codes
H411 Toxic to aquatic life with long lasting effects Hazardous to the aquatic environment, long-term hazard Category 2
Precautionary statements:

Description

Rivaroxaban is an orally active, direct inhibitor of Factor Xa (Ki = 0.4 nM), which is a crucial component of the intrinsic and extrinsic pathways of the blood coagulation cascade. It demonstrates >10,000-fold greater selectivity for Factor Xa compared to other related serine proteases. In various animal arterial and venous thrombosis models, rivaroxaban is reported to inhibit thrombin formation without prolonging bleeding time and has been approved for clinical use as an anticoagulant in the prevention of stroke and the treatment of venous thromboembolisms.

Related product price